What should be assessed prior to beginning doxorubicin treatment?

Prior to beginning doxorubicin treatment, it is essential to assess left ventricular cardiac function. Doxorubicin is known to have cardiotoxic effects, particularly at higher cumulative doses, which can lead to heart failure. By evaluating the patient's left ventricular function, typically through an echocardiogram or other cardiac imaging, healthcare providers can establish a baseline. This allows for monitoring any potential heart-related side effects throughout the treatment. If there are pre-existing issues with cardiac function, clinicians can make informed decisions about the appropriateness of doxorubicin for that patient, adjusting treatment plans or implementing protective strategies as necessary.

Liver enzyme assessment, kidney filtration rates, and baseline hemoglobin levels are indeed important in managing cancer patients and addressing potential toxicities related to chemotherapy. However, they are not as directly critical for doxorubicin specifically given its unique risk of cardiac toxicity. The focus on left ventricular function reflects the priority of preventing serious complications associated with this medication.